Does a same-price-at-every-dose promise hold?

Mostly, and the exclusions are where to look. 14 of the 51 companies published here promise one price at every dose; 2 publish an exclusion that takes part of it back, and 10 say plainly that the price follows the dose instead.

Who promises one price at every dose?

14 of 51: Eden, CoreAge Rx, Gala Health, Oak, Gimme Care, Cora Health, RxPros, Alan Health, Ivy Rx, Amble, TrimRx, HealthiCare, Enhance MD, and MyFastRx. The wording varies and the commitment does too, so here is each one's own sentence rather than our summary of it.

CoreAge Rx goes further than the phrase usually implies, and we say so as a site it pays a commission to: Same price at every dose, and CoreAge goes further than most: whatever price you lock in at checkout stays the same for all future months, regardless of dose increases. That is a price lock rather than a dose policy, and it is the strongest version of this claim in the roster.

What do the exclusions say?

2 of the 14 promises carry a published condition, and both are worth reading in full because they narrow the claim in different directions.

Eden excludes one thing: Eden publishes a Same Price at Every Dose policy covering dosage adjustments, excluding new-member promotions. That is a narrow, sensible carve-out — the promise covers the dose and not the discount that got you in.

Amble is the one that changes what the promise is. The badge above its plan table says Same price, every dose. The disclosure at the foot of the same page reads: The claim 'same price at every dose' is subject to the following: Pricing may change at any time due to supply or market conditions at the discretion of joinamble.com. Any 'same price at every dose' promotion expires within 24 hours of any price updates. And separately: Introductory or promotional pricing, including 'first month' offers, are not governed by the 'same price per dose' policy and only apply to full-price products as listed on the website.

Read those two sentences together and the promise is a promotion with a 24-hour life, revocable at the company's discretion, that does not cover the introductory price most new patients start on. It is disclosed — in full, on the same page — and it is not the commitment the badge above it describes.

What does a dose ladder cost at the top?

Several times the entry figure. 10 companies here say the price follows the dose, and the ones that publish the whole table are doing a reader more good than the ones that promise flatly and qualify it later. What that costs at the top:

Mochi Health publishes the cleanest version of a climbing ladder, dose by dose: Priced per dose, and published: 0.22 mg $60, 0.44 mg $70, 0.88 mg $82, 1.5 mg $92, 2.21 mg $96, 2.67 mg $99, 4.5 mg $151, 6.48 mg $189. Coby Health does it by month instead, which is the same information arranged the way a patient actually meets it: Month 1 (0.25mg): $159 · Month 2 (0.50mg): $199 · Month 3 (1.0mg): $229 · Month 4 (1.7mg): $249 · Month 5+ (2.4mg): $249. The advertised figure on both is the first rung.

The version to watch for is the third one: a price that moves with the dose and no table at all. Care Bare Rx's own words are Price varies by dose and medication prescribed, in their own words, and no tier table is published. Trava puts a warning under its dose selector — Your price will change if you need to adjust your dose for a better experience. — and publishes no figure for any dose above the first. Breeze Meds footnotes its plan screen with *Prices are based on lowest dosage rates. Higher dosages may reflect a higher rate. Please review product descriptions for dosage pricing. In each case the advertised number is a floor, and nothing on the site says how far above it the ceiling is.

Can one company do both at once?

One company does, and it is the sort of thing only a full read catches. HealthiCare states Your medication price does not increase with your prescribed dose beside the itemized receipt for its compounded plans — and, on the same site, prices the Wegovy tablet differently: Wegovy tablets are priced per dose tier.

Both sentences are true of their own products, so this is not a contradiction so much as a scope a reader has to notice. Its own tiers run $268.68 for wegovy tablets, doses 1 and 2 (1.5 mg and 4 mg) and $448.79 for wegovy tablets, maintenance doses (9 mg and 25 mg) — which is the part the flat-price sentence, read alone, would have led you to rule out.

Where is the promise actually published?

2 of the 14 companies making this claim make it somewhere a shopper cannot read it: on a plan screen behind a completed intake. Gala Health's version is Same Price. All Dosage Levels. One price. Forever. — and none of it appears on any public Gala page. TrimRx prints Same Price. All Dosage Levels. on an order summary 34 steps into its funnel.

That placement is the whole reason we walk these intakes. The terms are good; a reader comparing four browser tabs cannot use them.

So does the promise hold?

For most of the companies making it, yes — and that is the honest answer even though the interesting one would be no. 12 of the 14 promises in this roster are written flat, with no published condition on them, and one of them locks your price at checkout for good.

The promise fails in three specific ways, and they are the three to check before you believe one. It fails where an exclusion revokes it — Amble's expires 24 hours after any price update and does not cover the introductory rate. It fails by scope, where a company promises flatly on one product and prices another by tier, which is HealthiCare. And it is unusable where it is published behind an intake, which is Gala and TrimRx.

What it never means is that you are getting the cheapest treatment. The dearest flat price in this set is $1,399 at Eden, which is not a bargain merely because it does not move, and the entry rung of a ladder is often the cheapest month on offer anywhere — which is a different question, with a different answer.

What else do people ask about dose pricing?

• Does a GLP-1 price normally go up as the dose goes up?It depends entirely on the company, and both models are common here. 14 of the 51 companies published on this site say somewhere in their own material that the price is the same at every dose; 10 say the opposite, that the price follows the dose. Every one of those 24 companies is named on this page with the sentence it was classified on, read on August 31, 2026.
• What is the biggest price difference between a low dose and a high one?Midi Health, whose published rungs for unspecified GLP-1 run from $164 at sublingual glp-1, 0.075 mg to $460 at sublingual glp-1/gip, 7 mg — 2.8 times the entry figure, on one company's own published table.
• Do any of these promises have conditions attached?2 of the 14 publish an exclusion beside the promise. Eden's policy covers dosage adjustments while excluding new-member promotions. Amble's disclosure says the claim "expires within 24 hours of any price updates" and that introductory and first-month offers "are not governed by the 'same price per dose' policy". Both were read on August 31, 2026 and both are quoted in full on this page.
• Is a flat price better than a dose ladder?Not automatically. A flat price is easier to budget and it is a real commitment where the terms carry no exclusion. A published dose ladder is worse to budget and better to verify, because you can see exactly what the next step costs before you take it. The worst combination is neither: a company that neither promises a flat price nor publishes the tiers, which this roster also contains.

What we read, and where

Every sentence below was read on the company's own domain, or off a screen we reached ourselves, on August 31, 2026, and is quoted verbatim.

How the sets are built: a company is counted under The promise when its own material says the price does not change with the dose, under The ladder that climbs when its own material says it does, and under The exclusion attached to it when it publishes a condition on the promise. Each row above carries the sentence the classification was made on. Companies saying nothing either way on the pages recorded in their reviews are counted in neither, which is why the two sets do not add up to 51.

Nothing on this page is clinical advice, and none of it says which dose anybody should be on. This site has no clinician on its masthead and never invents one. What a dose does to a price is the only question here. Companies named as promising a flat price are quoted 5 times in the table above; companies named as pricing by dose, 6.

Some companies named here pay us a commission when a reader starts care through a marked link. The one marked link on this page is one of them, picked by rule and disclosed beside it. Nothing above is ordered by who pays — the spread table is ordered by the size of the multiple, which you can re-derive from each review's ladder. Who pays us · how we review · every review.

Kevin Turner · Reviews Editor · Checked August 2026